COVID-19 vaccination preferences during a pause in Johnson & Johnson vaccine administration

Abram L. Wagner; Felicia Zhang; Stefania Kerekes; Shu Fang Shih; Lili Zhao

doi:10.1016/j.jvacx.2023.100373

COVID-19 vaccination preferences during a pause in Johnson & Johnson vaccine administration

Abram L. Wagner^*, Felicia Zhang, Stefania Kerekes, Shu Fang Shih, Lili Zhao

^*Corresponding author for this work

Preventive Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

In April 2021, the US paused Janssen (J&J) COVID-19 vaccination because of reported blood clots post vaccination. This paper explores how vaccine decision-making–receiving a J&J vaccine right away vs waiting for a Pfizer vaccine–changed during the pause. In an opt-in internet-based survey April 2021 with 915 participants, 37 % were not vaccinated. Of these, 18 % would accept a J&J vaccine, 5 % would wait 1 month for a Pfizer vaccine, 25 % would wait 3 months, and 52 % would not want any vaccine. Among the unvaccinated, 56 % had heard of blood clots; 61 % of these did not want any vaccine, compared to 41 % of those who had not heard of blood clots. Moreover, among those vaccine hesitant in general, 11 % would still obtain a J&J vaccine if offered right away. These findings may suggest spillover of brand-specific adverse event concerns to the vaccine product as a whole.

Original language	English (US)
Article number	100373
Journal	Vaccine: X
Volume	15
DOIs	https://doi.org/10.1016/j.jvacx.2023.100373
State	Published - Dec 2023

Keywords

Adverse reactions
COVID-19
Risk perceptions
Vaccines

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jvacx.2023.100373

Cite this

@article{ae2c915539bd41be84d1003638f5666e,

title = "COVID-19 vaccination preferences during a pause in Johnson & Johnson vaccine administration",

abstract = "In April 2021, the US paused Janssen (J&J) COVID-19 vaccination because of reported blood clots post vaccination. This paper explores how vaccine decision-making–receiving a J&J vaccine right away vs waiting for a Pfizer vaccine–changed during the pause. In an opt-in internet-based survey April 2021 with 915 participants, 37 % were not vaccinated. Of these, 18 % would accept a J&J vaccine, 5 % would wait 1 month for a Pfizer vaccine, 25 % would wait 3 months, and 52 % would not want any vaccine. Among the unvaccinated, 56 % had heard of blood clots; 61 % of these did not want any vaccine, compared to 41 % of those who had not heard of blood clots. Moreover, among those vaccine hesitant in general, 11 % would still obtain a J&J vaccine if offered right away. These findings may suggest spillover of brand-specific adverse event concerns to the vaccine product as a whole.",

keywords = "Adverse reactions, COVID-19, Risk perceptions, Vaccines",

author = "Wagner, {Abram L.} and Felicia Zhang and Stefania Kerekes and Shih, {Shu Fang} and Lili Zhao",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

month = dec,

doi = "10.1016/j.jvacx.2023.100373",

language = "English (US)",

volume = "15",

journal = "Vaccine: X",

issn = "2590-1362",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - COVID-19 vaccination preferences during a pause in Johnson & Johnson vaccine administration

AU - Wagner, Abram L.

AU - Zhang, Felicia

AU - Kerekes, Stefania

AU - Shih, Shu Fang

AU - Zhao, Lili

PY - 2023/12

Y1 - 2023/12

N2 - In April 2021, the US paused Janssen (J&J) COVID-19 vaccination because of reported blood clots post vaccination. This paper explores how vaccine decision-making–receiving a J&J vaccine right away vs waiting for a Pfizer vaccine–changed during the pause. In an opt-in internet-based survey April 2021 with 915 participants, 37 % were not vaccinated. Of these, 18 % would accept a J&J vaccine, 5 % would wait 1 month for a Pfizer vaccine, 25 % would wait 3 months, and 52 % would not want any vaccine. Among the unvaccinated, 56 % had heard of blood clots; 61 % of these did not want any vaccine, compared to 41 % of those who had not heard of blood clots. Moreover, among those vaccine hesitant in general, 11 % would still obtain a J&J vaccine if offered right away. These findings may suggest spillover of brand-specific adverse event concerns to the vaccine product as a whole.

AB - In April 2021, the US paused Janssen (J&J) COVID-19 vaccination because of reported blood clots post vaccination. This paper explores how vaccine decision-making–receiving a J&J vaccine right away vs waiting for a Pfizer vaccine–changed during the pause. In an opt-in internet-based survey April 2021 with 915 participants, 37 % were not vaccinated. Of these, 18 % would accept a J&J vaccine, 5 % would wait 1 month for a Pfizer vaccine, 25 % would wait 3 months, and 52 % would not want any vaccine. Among the unvaccinated, 56 % had heard of blood clots; 61 % of these did not want any vaccine, compared to 41 % of those who had not heard of blood clots. Moreover, among those vaccine hesitant in general, 11 % would still obtain a J&J vaccine if offered right away. These findings may suggest spillover of brand-specific adverse event concerns to the vaccine product as a whole.

KW - Adverse reactions

KW - COVID-19

KW - Risk perceptions

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85171676779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85171676779&partnerID=8YFLogxK

U2 - 10.1016/j.jvacx.2023.100373

DO - 10.1016/j.jvacx.2023.100373

M3 - Article

C2 - 37674932

AN - SCOPUS:85171676779

SN - 2590-1362

VL - 15

JO - Vaccine: X

JF - Vaccine: X

M1 - 100373

ER -

COVID-19 vaccination preferences during a pause in Johnson & Johnson vaccine administration

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this